GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Almirall SA (WBO:ALM) » Definitions » Net Income Including Noncontrolling Interests

Almirall (WBO:ALM) Net Income Including Noncontrolling Interests : €11.7 Mil (TTM As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Almirall Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Almirall's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2024 was €7.4 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 was €11.7 Mil.

Almirall Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Almirall's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Almirall Net Income Including Noncontrolling Interests Chart

Almirall Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only 105.91 74.28 -40.86 4.28 -38.47

Almirall Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23 Mar24
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 7.70 4.32 - 7.40

Almirall Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €11.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Almirall Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Almirall's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Almirall (WBO:ALM) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Almirall SA (WBO:ALM) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
XMAD:FAE XMAD:RJF XTER:MRK ZTS NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ NBIX SZSE:000538 NSE:DIVISLAB BOM:532321 TSE:4507 HKSE:03692 VTRS TSE:4523 BOM:500124 XPAR:IPN NSE:TORNTPHARM
Traded in Other Exchanges
LBTSF:USA 0O9B:UK ALM:Spain E2Z:Germany
Address
Ronda General Mitre 151, Barcelona, ESP, 08022
Website
http://www.almirall.es
Almirall SA is a Spain-based company engaged in development, manufacture, and selling pharmaceutical products across a range of therapeutic areas. It aims to provide treatments in areas of dermatology, respiratory, gastrointestinal, central nervous systems, and other specialties. The company operates in five segments: Sales of its own network, sales of licensees, Research and developments, Sales of Therapeutic dermatological products in the U.S., and Corporate management. The medical dermatology business in the Europe is the key driver of the company's operation. Other than Europe, the company also operates in the Americas, Asia, Africa, and Oceania through subsidiaries.

Almirall (WBO:ALM) Headlines

From GuruFocus

Alfi: Solid Growth Potential Lies Ahead

By Ishan Majumdar Ishan Majumdar • 06-02-2021

ALFI Inc: A Little Known Yet Compelling Ad-Tech Play

By Ishan Majumdar Ishan Majumdar • 05-07-2021